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Specific bone marrow (BM) niches are critical for
hematopoietic stem cell (HSC) function during both
normal hematopoiesis and in stem cell transplanta-
tion therapy. We demonstrate that the guidance
molecule Robo4 functions to specifically anchor
HSCs to BM niches. Robo4-deficient HSCs dis-
played poor localization to BM niches and drastically
reduced long-term reconstitution capability while re-
taining multilineage potential. Cxcr4, a critical regu-
lator of HSC location, is upregulated in Robo4/
HSCs to compensate for Robo4 loss. Robo4 deletion
led to altered HSC mobilization efficiency, revealing
that inhibition of both Cxcr4- and Robo4-mediated
niche interactions are necessary for efficient HSC
mobilization. Surprisingly, we found that WT HSCs
express very low levels of Cxcr4 and respond poorly
to Cxcr4 manipulation relative to other hematopoi-
etic cells. We conclude that Robo4 cooperates with
Cxcr4 to endow HSCs with competitive access to
limited stem cell niches, and we propose Robo4 as
a therapeutic target in HSC transplantation therapy.
INTRODUCTION
The tremendous potential of stem cells to provide a complete
and permanent cure for a wide range of human disorders makes
progress in improving the safety and efficiency of cell-based
therapies a top priority in modern medicine. Successful hemato-
poietic cell transplantations have been performed for more than
50 years and have made HSCs the paradigm for stem cell
therapy. Still, the morbidity andmortality of hematopoietic trans-
plant recipients are unacceptably high and transplants are there-
fore reserved for patients with few other treatment options.
By investigating the molecular mechanisms of HSC interaction
with the bone marrow (BM) microenvironment, our goal is to
enable specific and efficient manipulation of both HSC mobiliza-
tion and engraftment.
Because mobilized peripheral blood (PB) is an increasingly
common source of HSCs, transplantation therapy involves72 Cell Stem Cell 8, 72–83, January 7, 2011 ª2011 Elsevier Inc.HSC movement both into and out of the BM. In mice, as well
as in humans, combined administration of cytoxan (cyclophos-
phamide) and G-CSF (Cy/G treatment) induces self-renewing
divisions of BM HSCs, resulting in an expansion of the HSC
pool followed by migration of HSCs to the blood stream (Morri-
son et al., 1997; Passegue´ et al., 2005; Wright et al., 2001).
More recently, AMD3100, an antagonist of the G protein-
coupled receptor Cxcr4, has been used to mobilize hematopoi-
etic cells (Broxmeyer et al., 2005; Liles et al., 2003; Watt and
Forde, 2008). In contrast to Cy/G, AMD3100-induced mobiliza-
tion is rapid, with increased numbers of progenitors detected
in the blood 1 hr after administration of a single dose of drug,
and thus does not involve cell expansion. Upon transplantation,
intravenously injected HSCs must find their way back to the BM
and engraft. Most likely, HSCs home in response to chemokines,
including the Cxcr4 ligand Sdf1 (also known as Cxcl12), followed
by adhesion to the niche by engaging in specific interactions with
cellular and matrix components. Engraftment of transplanted
HSCs requires partial or complete myeloablation to allow donor
HSCs access to HSC-supportive niches. The ability to long-term
engraft is a defining and unique property of HSCs and critically
important for both normal hematopoietic development and
transplantation therapy.
Sdf1 andCxcr4 play pivotal roles in HSC location and function.
Mice deficient in either Sdf1 or Cxcr4 die during late embryogen-
esis and lack BM hematopoiesis (Nagasawa et al., 1996; Zou
et al., 1998). As described above, the Cxcr4 antagonist
AMD3100 can be used to mobilize hematopoietic progenitors
from the BM to PB in mice and humans (Broxmeyer et al.,
2005; Watt and Forde, 2008), and Cxcr4-blocking antibodies
impair HSC engraftment (Peled et al., 1999). In addition, HSCs
actively migrate toward Sdf1 in transwell migration assays
(Lapidot, 2001; Wright et al., 2002), and recent data suggest
that HSCs specifically localize next to BM cells expressing
high levels of Sdf1 (Sugiyama et al., 2006). Thus, there is exten-
sive evidence supporting critical roles for Sdf1 and Cxcr4 in
regulating HSC location.
Surprisingly, however, deletion of Cxcr4 in adulthood results in
HSCs capable of homing and engraftment (Nie et al., 2008;
Sugiyama et al., 2006). In addition, many cells other than HSCs
express Cxcr4, making it unlikely that Cxcr4, alone, specifies
HSC location to stem-cell-supportive niches. In search of
HSC-specific receptors capable of specifying cell location, we
recently identified the single-transmembrane receptor Robo4
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Robo4 Regulates HSC Location to Bone Marrow Nicheson HSCs by gene expression microarray analysis (Forsberg
et al., 2005). A subsequent report confirmed that Robo4 marks
long-term reconstituting HSCs (Shibata et al., 2009). Robo4,
like its family members Robo1-3, is capable of regulating cell
location by responding to the Slit family of secreted ligands
(Kaur et al., 2006; Park et al., 2003; Seth et al., 2005; Suchting
et al., 2005). Other than HSCs, Robo4 expression seems
restricted to endothelial cells, where it functions to regulate
blood vessel sprouting (Huminiecki et al., 2002; Park et al.,
2003). Robo4/ mice, though grossly normal, have defects in
VEGF- and Slit-induced regulation of vascular integrity and
angiogenesis (Jones et al., 2008; London et al., 2010; Marlow
et al., 2010). Here, we show that Robo4 acts as an HSC-specific
adhesion molecule that cooperates with Cxcr4 to localize HSCs
to BM niches.
RESULTS
Robo4 Expression Is Restricted to HSCs Tightly
Associated with BM Niches
Our previous gene expression microarray analysis showed that
Robo4 is expressed at higher levels by HSCs compared to
MPP, Cy/G-mobilized HSCs (M-HSCs), and leukemic HSCs
(L-HSCs) (Forsberg et al., 2005, 2010). We verified these results
by qRT-PCR and extended the analysis to include multiple BM
cell types representing the major hematopoietic progenitor pop-
ulations and lineages. We found that Robo4 is very selectively
expressed by HSCs and downregulated upon differentiation
and mobilization and in leukemogenesis (Figures 1A and 1B).
Substantial numbers of M-HSCs and L-HSCs are found in the
blood, spleen, and liver (Morrison et al., 1997; Passegue´ et al.,
2004), so Robo4 downregulation may facilitate exit from HSC
niches in the BM. Intriguingly, Robo4 transcripts were barely
detectable in fetal liver HSCs and increased significantly in BM
HSCs during fetal to adult development (Figure 1C), further
emphasizing the specificity of Robo4 expression to HSCs
located in the BM. Cell surface staining via a monoclonal
antibody specific for Robo4 (Figure 1E) showed that Robo4
protein is robustly expressed by all adult BM HSCs, with lower
levels on ST-HSCs and MPP, and absent from other hematopoi-
etic cell types (Figure 1D; for flow cytometry gating strategies
see Figure S1A available online), in agreement with the qRT-
PCR data (Figure 1A). Less than 1% of total nucleated BM cells
are Robo4 positive, so Robo4 is an excellent HSC-specific
marker.
Because different Robo receptors may be functionally redun-
dant, we also analyzed the expression of Robo1, 2, and 3.
Previous studies have reported that circulating hematopoietic
cells express Robo1 and respond to the Robo ligand Slit2 (Pra-
sad et al., 2007; Wu et al., 2001). In addition, it has been sug-
gested that Robo4 heterodimerization with Robo1 is required
for Robo4 response to Slits (Sheldon et al., 2009). However,
we did not detect robust expression for either Robo1, 2, or 3
in purified hematopoietic cell populations by using qRT-PCR
under conditions that readily detected these transcripts in brain
tissue (data not shown). Additionally, we were unable to detect
Robo1 on any BM or PB cell type, including HSCs, by flow cy-
tometry by means of a monoclonal antibody that detected
Robo1 on WT, but not Robo1/, brain cells (Figure S1B).These data are consistent with a recent report (Shibata et al.,
2009) and suggest that Robo4 is the predominant Robo
receptor on hematopoietic cells. Importantly, Robo4 expression
is restricted to HSCs that maintain tight interactions with the
BM niche.Reduced BM Interaction of HSCs Lacking Robo4
To assess the functional role of Robo4 in vivo, we analyzed the
frequencies of hematopoietic cells in the BM, spleen, and blood
of Robo4-deficient mice. Strikingly, analysis of cell frequencies
in the BM under normal, nonstress conditions revealed that
Robo4/ mice displayed a significant decrease in HSC
frequencies, whereas other cell types were not affected (Fig-
ure 2A). This decrease in HSC BM frequencies was mirrored
by a reproducible increase in HSC frequencies in PB (Fig-
ure 2B). HSC numbers in the spleen were not affected (Fig-
ure S2A). To test whether the decrease in HSC BM frequencies
reflects defects in HSC proliferation, we assayed proliferative
activity in vitro and in vivo. We detected no differences in the
cell cycle status of Robo4/ HSCs or progenitors compared
to WT mice (Figures S2B and S2C). We also tested the
in vitro expansion rates of WT and Robo4/ HSCs, and
whether the putative Robo4 ligand Slit2 elicits a proliferative
response on WT HSCs, without detecting significant differ-
ences (Figures S2D and S2E). Consistent with these data,
Robo4/ HSCs were as able as WT HSCs to restore hemato-
poiesis after weekly injections of the cytotoxic agent 5-fluoro-
uracil (5-FU) (Figure S2F). Thus, loss of Robo4 does not
significantly impair HSC proliferative capacity. Lower HSC
frequencies in Robo4/ BM may instead be explained by
reduced HSC retention in the BM. This is supported by the
HSC increase in PB in Robo4/ mice (Figure 2B) and also
by downregulation of Robo4 in M-HSCs and L-HSCs (Figure 1B)
as mobilization and leukemia lead to higher numbers of HSCs
in the PB, spleen, and liver (Morrison et al., 1997; Passegue´
et al., 2004).Robo4–/– HSCs Display Poor BM Engraftment,
but Normal Differentiation Capacity
To test whether Robo4 plays a role in HSC reconstitution of
hematopoiesis upon transplantation, we competitively trans-
planted 100 HSCs from WT and Robo4/ mice into congenic
hosts and monitored PB cell readout for 16 weeks. Robo4/
HSCs performed as well as WT HSCs up to 3 weeks, but failure
to provide sustained hematopoietic expansion over time
resulted in a significant difference in PB cell readout beyond
6 weeks (Figure 2C). The ratios of mature myeloid, B, and
T cells were not significantly affected by the loss of Robo4
(Figure 2D). Interestingly, we detected no differences between
WT and Robo4/ HSCs in in vivo spleen colony-forming assays
(CFU-S12) (Figure 2E), indicating that the impaired transplanta-
tion defect is specific for the BM. Indeed, analysis of the BM of
long-term reconstituted animals revealed significantly fewer
Robo4/ HSCs compared to WT HSCs (Figure 2F). These
data show that Robo4/ HSCs display a specific and signifi-
cantly impaired ability to engraft in the BM. However, the
Robo4/ HSCs that do engraft are maintained over time and
produce normal ratios of mature cells.Cell Stem Cell 8, 72–83, January 7, 2011 ª2011 Elsevier Inc. 73
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Figure 1. Robo4 Is Selectively Expressed by BM-Localized HSCs
(A) Relative levels of Robo4 transcripts in purified BM populations by qRT-PCR compared to HSCs. Data shown are from four independent experiments with
qPCR reactions performed in triplicate.
(B) Relative Robo4 mRNA levels by qRT-PCR in WT HSCs, mobilized HSCs (M-HSCs), and leukemic HSCs (L-HSCs).
(C) Quantitative RT-PCR revealed that Robo4 expression increases as HSCs (defined as ckit+LinSca1+ cells) transition from fetal liver (L) to BM during devel-
opment.
(D) Cell surface Robo4 expression on BM subpopulations from WT mice, demonstrating highly selective Robo4 expression on HSCs.
(E) Flow cytometry plots of ckit+LinSca1+ BM cells from WT and Robo4/ mice demonstrating the specificity of the antibody for Robo4.
BM, bone marrow. Error bars represent SEM. *p < 0.005; **p < 0.0001. See also Figure S1.
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Robo4 Regulates HSC Location to Bone Marrow NichesHSCs Lacking Robo4 Mobilize Less Efficiently
with Cy/G Treatment
Decreased BM frequencies at steady-state (Figure 2A) and
impaired BM engraftment (Figures 2C and 2E) of Robo4/
HSCs suggest that Robo4 mediates adhesive interactions
between HSC and BM niches. Consequently, Robo4 downregu-
lation upon Cy/G-induced mobilization (Figure 1B) may be
necessary for efficient HSC relocation from BM to PB. We there-
fore hypothesized that Robo4/ HSCs would be mobilized with
greater efficiency compared to WT HSC. To test this directly, we
subjected WT and Robo4/ mice to the Cy/G injection74 Cell Stem Cell 8, 72–83, January 7, 2011 ª2011 Elsevier Inc.schedule of Figure 3A. As expected, WT mice displayed robust
increases in BM HSC numbers by day 2 (20-fold; Figure 3B)
and high numbers of PB HSCs starting at day 2 with a further
significant increase by day 4 (Figure 3C). Robo4/ HSCs in
the BM expanded to similar levels as WT HSCs (Figure 3B),
consistent with their normal in vitro proliferation rates and prolif-
erative capacity with in vivo 5-FU treatment (Figure S2).
However, contrary to our hypothesis that Robo4/ HSCs
would relocate to the blood more efficiently because of weak-
ened niche interactions, we detected significantly fewer
Robo4/ HSCs in the PB at day 2 (Figure 3C). This impaired
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Figure 2. Robo4–/– HSCs Displayed
Impaired BM Localization at Steady-State
and upon Transplantation
(A and B) HSC frequencies were significantly lower
in the BM (A) and higher in PB (B) inRobo4/mice
compared to WT mice. Other cell types were not
affected by Robo4 loss.
(C) Robo4/ HSCs had drastically impaired long-
term reconstitution potential upon transplantation
compared to WT HSCs. Total donor-derived cells
in PB at the indicated time points after competitive
reconstitution with 100 WT and Robo4/ HSCs
are shown.
(D) Relative lineage readout was not affected by
Robo4 deficiency. The ratios of mature B, T, and
myeloid cells in PB, BM, and spleen >16 weeks
after competitive transplantation of 100 WT and
Robo4/ HSCs are shown.
(E)Robo4/HSCs gave rise to in vivo spleen colo-
nies with normal frequencies. Lethally irradiated
mice were transplanted with either 100 Robo4/
or WT HSCs. Twelve days after transplantation,
spleens were harvested for CFU-S analysis.
(F) The number of Robo4/ HSCs and progenitor
cells in the BM of transplanted mice was signifi-
cantly lower thanWT cells at >16weeks posttrans-
plantation.
All data are from at least three independent exper-
imentswith at least threemiceper groupper exper-
iment (n R 9). Error bars represent SEM.
**p < 0.004; ***p < 0.0006. See also Figure S2.
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Robo4 Regulates HSC Location to Bone Marrow Nichesmobilization was specific for HSCs, as MPP numbers in the PB
were similar between WT and Robo4/ mice at all time points
(Figure 3D).
Sdf1 and Cxcr4 Are Upregulated to Compensate
for Loss of Robo4
To determine whether upregulation of other cell surface recep-
tors accounts for the impaired HSC mobilization in Robo4/
mice, we compared the expression of potentially redundant
receptors in WT and Robo4/ HSCs. We did not detect
compensatory increases in Robo1, Robo2, or Robo3 mRNA
levels in Robo4/ HSCs (data not shown), and we failed to
detect cell surface Robo1 on either WT or Robo4/ HSCs (Fig-
ure S1B and data not shown). Likewise, we detected no differ-
ences in the levels of Vcam1, CD31, or Esam1 (Figure S3A).
Because Cxcr4 has been suggested to retain HSCs in BMniches
by interaction with Sdf1-expressing cells, we assayed the effect
of Robo4 deficiency on Cxcr4 expression. Strikingly, we
observed a 3-fold increase in Cxcr4 transcript levels inRobo4/
mice (Figure 3E). Transcription did not appear to be regulated by
levels of histone H3 trimethylation of lysine 4 (H3K4Me3) and 27
(H3K27Me3) (Figures S3B and S3C). However, elevated Cxcr4
transcript levels were paralleled by increased cell surface levels
of Cxcr4 on HSCs, but not on MPP or myeloid progenitor cellsCell Stem Cell 8, 72–(Figure 3F). In addition, we observed an
increase in Sdf1 mRNA levels in BM
stromal cells inRobo4/mice (Figure 3G).
Interestingly, expression of Slit2 was notaffected by loss of Robo4 (Figure 3H). These results demon-
strated a specific upregulation of the Sdf1/Cxcr4 axis in
Robo4/ BM.
Intriguingly, Cy/G treatment led to decreased Sdf1 expression
in BM stromal cells in both WT and Robo4/ mice (Figure 3G).
In addition, Cxcr4 cell surface levels increased on BM HSCs,
but decreased on HSCs in PB upon Cy/G treatment (Figure 3I).
These results suggest that daily G injections eventually over-
come Cxcr4-mediated retention of HSC, and that only the high-
est Cxcr4-expressing HSCs remain in the BM by day 4. The
observation that Cy/G treatment affects Cxcr4 levels also
support our hypothesis that the elevated levels of Cxcr4 in
Robo4/ HSCs accounts for their poor mobilization by day 2
(Figure 3C).
Inhibition of Cxcr4 Restores Cy/G-Induced HSC
Mobilization Efficiency in Robo4–/– Mice
If upregulation of Cxcr4 acts as a compensatory mechanism to
counteract the loss of Robo4, inhibition of Cxcr4-mediated
interaction with BM niche components should restore the mobi-
lization efficiency of Robo4/ HSCs. To test this possibility
directly, we performed mobilization assays by using Cy/G
combined with the Cxcr4 inhibitor AMD3100 according to the
injection schedule of Figure 4A. BM and PB analysis of HSCs83, January 7, 2011 ª2011 Elsevier Inc. 75
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Figure 3. Robo4–/– HSCs Mobilized Less
Efficiently with Cy/G Treatment because of
Upregulation of Cxcr4
(A) Cy/G injection and tissue analysis schedule.
(B) HSC (ckit+LinSca1+Flk2 cells) expansion in
the BM in response to Cy/G was normal in
Robo4/ mice.
(C) Fewer Robo4/ HSCs relocated to the PB at
day 2 of Cy/G treatment. No differences between
WT and Robo4/ HSCs were observed at day 4.
(D) The number of MPP (ckit+LinSca1+Flk2+ cells)
mobilized to the blood was not affected by Robo4
deficiency.
(E) Cxcr4 mRNA levels were significantly higher in
Robo4/ HSCs compared to WT HSCs.
(F) Robo4/ HSCs displayed higher Cxcr4 cell
surface levels than WT HSCs by flow cytometry
analysis. No differences were observed for MPP
or myeloid progenitors.
(G) BM stromal (CD45Ter119) cells from
Robo4/ mice expressed higher levels of Sdf1
than WT stromal cells. Cy/G treatment led to
downregulation of Sdf1 in both WT and Robo4/
stromal cells.
(H) Slit2 mRNA levels in BM stromal cells were not
affected by loss of Robo4.
(I) Cxcr4 cell surface levels increased on both WT
and Robo4/ BM HSCs, but decreased on PB
HSCs upon Cy/G treatment.
Data represent at least three (B–G) or two (H and I;
n R 10) independent experiments with at least
three mice per cohort per experiment (B–D;
n R 9). Error bars represent SEM. *p < 0.05;
**p < 0.001. See also Figure S3.
Cell Stem Cell
Robo4 Regulates HSC Location to Bone Marrow Nichesin WT mice revealed no significant differences between treat-
ment with Cy/G alone or Cy/G plus AMD3100 (Figure 4B).
Strikingly, combined Cy/G and AMD3100 treatment of
Robo4/ mice resulted in significantly better HSC mobilization
than Cy/G alone, restoring Robo4/ HSC levels in the PB to
that of WT HSC (Figure 4B). This effect was unique to HSCs,
as there was no differential response between WT and
Robo4/ MPP under these conditions (Figure 4C). These
results support our hypothesis that upregulation of Cxcr4
compensates for loss of Robo4-mediated interactions between
HSC and BM niches.Differential Mobilization of Hematopoietic Stem
and Progenitors by AMD3100
We also investigated the effects of AMD3100 alone on HSC
mobilization in WT and Robo4/ mice. Although progenitor
cell numbers increased robustly in the blood 1 hr after two
sequential AMD3100 injections, we found surprisingly few
circulating HSCs in WT mice (Figure 4D). These results were76 Cell Stem Cell 8, 72–83, January 7, 2011 ª2011 Elsevier Inc.consistent with different injection sched-
ules and routes (i.v., s.c.). Thus, MPP
and myeloid progenitors were mobilized
more efficiently with AMD3100 than
were HSCs.
We hypothesized that the relatively low
mobilization efficiency with AMD3100 isdue to HSC retention in BM niches by non-Cxcr4-mediated,
HSC-specific interactions such as Robo4 adhesion. Intriguingly,
the efficiency of AMD3100-induced HSC, but not progenitor,
mobilization was much greater in Robo4/ mice compared to
WTmice (Figure 4E). In vitro colony-forming assays were consis-
tent with these data (Figure S4). This supports the hypothesis
that Robo4 acts to retain HSCs in the BM niche in collaboration
with Cxcr4, and that Cxcr4 upregulation compensates for Robo4
loss.
HSCs Express Relatively Low Levels of Cxcr4 and
Migrate Less Efficiently toward Sdf1
When investigating Cxcr4 expression (Figure 3F), we were
surprised to find very low Cxcr4 cell surface levels on WT HSCs.
Those results and the differential response of HSCs
and progenitors to AMD3100 (Figure 4D) prompted us to investi-
gate the relative importance of Cxcr4 for different BM subpopula-
tions. We first compared Cxcr4 expression levels by qRT-PCR. In
agreement with published literature, we found very high levels of
Cxcr4 transcripts in B cells (Figure 5A). HSCs also expressed
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Figure 4. Robo4–/– HSCs Were More
Responsive to AMD3100 than Were WT
HSCs
(A) Injection and analysis schedule for (B) and (C).
PB was analyzed 1 hr after AMD3100 injections on
day 2.
(B)Robo4/HSCs, but not WTHSCs, weremobi-
lized more efficiently by Cy/G+AMD3100 than by
Cy/G alone.
(C) Mobilization of MPP was more efficient when
AMD3100 was added to the Cy/G treatment. No
differences were observed between WT and
Robo4/ MPP.
(D) Hematopoietic progenitors were more effi-
ciently mobilized with AMD3100 compared to
HSCs. WT mice were subjected to two AMD3100
injections 1 hr apart, with PB analysis 1 hr after
the second injection.
(E) Robo4/ HSCs were more efficiently mobi-
lized with AMD3100 compared to WT HSCs. No
differences were observed between WT and
Robo4/ MPP or myeloid progenitors. Injection
and analysis schedule as in (D).
MPP, multipotent progenitors; MyPro, myeloid
progenitors (LincKit+Sca1 cells). Error bars
represent SEM. Data represent at least three inde-
pendent experiments with at least three mice per
cohort per experiment (n R 9). *p < 0.03;
**p < 0.01. See also Figure S4.
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Robo4 Regulates HSC Location to Bone Marrow NichesCxcr4 mRNA, although at lower levels than several other cell
types. A very similar pattern was observed when analyzing
Cxcr4 cell surface levels by flow cytometry (Figure 5B), revealing
that several cell types that aremore numerous than HSCs display
much higher levels of Cxcr4 (Figure 5C).
We therefore tested the functional consequences of differen-
tial Cxcr4 levels by comparing the in vitro migratory response
of different populations to Sdf1 (Aiuti et al., 1997). Although we
detected robust and reproducible HSC migration toward Sdf1,
cell types expressing higher levels of Cxcr4 (e.g., MPP, myeloid
progenitors, and B cells) migrated with significantly greater
efficiency (Figures 5C and 5D). These results suggest that the
Sdf1/Cxcr4 axis affects hematopoietic progenitor cells to
a greater extent than HSCs, consistent with the higher mobiliza-
tion efficiency of progenitors with AMD3100 in vivo (Figures
4B–4D).
Because Robo receptors on brain and endothelial cells are
capable of mediating migratory responses to Slit ligands, we
hypothesized that Slit2 might attract or repel HSCs. However,
we did not detect HSC migration toward Slit2 (data not shown)
under conditions where HSCmigration toward Sdf1 is readily de-
tected (Figure 5D). Because Slits can act as repellants (Park
et al., 2003; Seth et al., 2005), we also tested whether Slit2 in-Cell Stem Cell 8, 72–hibited HSC migration toward Sdf1.
Neither preincubation of HSC with Slit2
nor addition of Slit2 to Sdf1-containing
bottom wells had an effect on Sdf1-
induced HSCmigration (Figure S5A); like-
wise, migration of CD4+ T cells was not
affected (Figure S5B). We confirmed
that Slit2 was biologically active bydemonstrating inhibition of HL60 cell migration toward fMLP
(Figure S5C). Thus, Robo4 expression on HSCs does not trans-
late to detectable migratory responses in vitro.
Robo4 and Cxcr4 Cooperate to Localize HSCs to the BM
upon Transplantation
The upregulation of Cxcr4 upon loss of Robo4 (Figures 3E and
3F) and the increased mobilization efficiency with AMD3100 in
Robo4/ mice (Figure 4E) prompted us to investigate the role
of Cxcr4 and Robo4 on HSC localization to the BM upon trans-
plantation. We first tested whether preincubation with
AMD3100 was capable of inhibiting HSC migration toward
Sdf1 in transwell migration assays. Indeed, we detected
a dose-dependent decrease in migration of both WT and
Robo4/ HSCs, with complete inhibition at 12.5 mM of
AMD3100 (Figure 6A; Figure S6).
We then transplanted untreated and AMD3100-treated HSCs
from WT and Robo4/ mice into lethally irradiated recipients.
Three hours postinjection, BM, spleen, and PB were analyzed
for numbers of donor cells. In contrast to in vitromigration, where
AMD3100 completely abolished migration of HSCs toward Sdf1
(Figure 6A), AMD3100 was not expected to completely inhibit
homing in vivo because Cxcr4/ HSCs are capable of BM83, January 7, 2011 ª2011 Elsevier Inc. 77
C
X
C
R
4 
m
R
N
A
 L
ev
el
s
* *
**
*
**
*
HS
C
MP
P
CM
P
GM
P
ME
P
CL
P
B 
Ce
lls
T C
ell
s
My
elo
id
Er
yth
roi
d
A
%
 C
X
C
R
4+
 C
el
ls
HS
C
MP
P
CM
P
GM
P
ME
P
CL
P
B 
Ce
lls
T C
ell
s
My
elo
id
Er
yth
roi
d
C
My
Pr
o
* ***
***
HS
C
MP
P
B 
Ce
lls
%
 o
f C
el
ls
 M
ig
ra
tin
g
D
%
of
 M
ax
CXCR4
B Cells
HSC
B Figure 5. HSCs Expressed Lower Levels of Cxcr4
and Migrated Less Efficiently toward Sdf1
Compared to More Mature Hematopoietic
Subpopulations
(A–C) HSCs expressed relatively low levels of Cxcr4 by (A)
qRT-PCR analysis and (B, C) flow cytometry cell surface
staining.
(D) Transwell migration assays revealed that HSC migra-
tion efficiency toward Sdf1 was lower than that of cells
expressing higher levels of Cxcr4.
Data represent at least three independent experiments.
Error bars represent SEM. *p < 0.03; **p < 0.0001;
***p < 0.00001. See also Figure S5.
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Robo4 Regulates HSC Location to Bone Marrow Nichesengraftment (Nie et al., 2008; Sugiyama et al., 2006). Consistent
with this observation, AMD3100 preincubation of WT cells re-
sulted in a 2-fold reduction in donor cells localizing to the BM
(Figure 6B). Loss ofRobo4 led to a comparable decrease in trans-
planted cells in the BM (Figure 6B), a notable result because this
decrease occurred despite the elevated levels of Cxcr4 on
Robo4/ HSCs (Figure 3F). Strikingly, treatment of Robo4-defi-
cient cells with AMD3100 resulted in a further decrease in BM
localization (Figure 6B), demonstrating that both Robo4 and
Cxcr4 function to localize HSCs to the BM upon transplantation.
Consistentwith thedecreasednumber of transplanted cells in the
BM for each condition, a reciprocal increase of donor cells was
detected in the bloodstream (Figure 6C). Interestingly, there
were no differences in localization to the spleen (Figure 6D),
supporting the BM-specific effects observed with Robo4/
HSCs in steady state, CFU-S, and multilineage reconstitution
assays (Figure 2; Figure S2). These data demonstrate that
Robo4 and Cxcr4, individually and together, regulate HSC local-
ization to the BM.
DISCUSSION
Robo4 Regulates HSC Interactions with BM Niches
We have identified Robo4 as a critical regulator of HSC locali-
zation to the BM. Robo4 expression was very low in fetal
HSCs residing in the liver, but increased during development
concurrent with the establishment of BM hematopoiesis (Fig-
ure 1C). Thus, Robo4 is very selectively expressed by adult78 Cell Stem Cell 8, 72–83, January 7, 2011 ª2011 Elsevier Inc.BM HSCs and downregulation occurs not
only during normal differentiation, but also
upon HSC mobilization and in leukemogenesis
(Figures 1A and 1B). Intriguingly, these pro-
cesses all involve alterations in cell location,
concomitant with a surge in proliferation.
Although we have not yet assessed the
functional role of Robo4 in leukemic transfor-
mation, its downregulation in L-HSCs is
consistent with the proposed tumor sup-
pressor functions of Robo receptors (Dallol
et al., 2002; Legg et al., 2008; Marlow et al.,
2008). Thus, downregulation of Robo4 may
be a prerequisite for HSC exit out of BM niches
regulating HSC function. Because very few BM
cells are Robo4 positive, our data suggest that
Robo4 is an excellent HSC-specific marker. Itwill be interesting to investigate the utility of Robo4, alone
and in combination with other highly specific HSC markers
such as Esam1 (Ooi et al., 2009), in simplified HSC purification
protocols.
Consistent with its HSC-specific expression, Robo4 deletion
led to perturbations in HSC localization during steady-state (Fig-
ure 2A), in short-term homing (Figure 6) and long-term reconsti-
tution assays (Figures 2C and 2F), and upon mobilization with
both Cy/G and AMD3100 (Figures 3 and 4). These effects were
specific for BM localization, as spleen readouts and in vitro
HSC properties were not affected by Robo4 loss (Figures 2E
and 6D; Figure S2). Decreased Robo4/ HSC frequencies in
BM at steady-state indicates that Robo4 stabilizes interactions
between HSC and BM niche components. Such a function is
consistent with the poor BM localization of Robo4/ HSCs in
short-term homing assays and dramatically impaired long-term
engraftment. Importantly, the Robo4/ HSCs that did engraft
had normal differentiation capacity (Figure 2D). Robo4 function
therefore appears restricted to regulating HSC interactions
with the BM niche and does not appear to affect cell fate choice.
Furthermore, Robo4/ HSCs were more efficiently mobilized
with AMD3100 than were WT HSCs (Figure 4E), indicating that
Robo4 acts to retain HSCs in BM niches. In contrast to the
increased relocation to the blood with AMD3100, Cy/G-induced
HSC mobilization was impaired in Robo4/ mice (Figure 3C).
Investigation of the underlying molecular mechanisms revealed
that Cxcr4 was upregulated in Robo4/ HSCs (Figures 3E and
3F), suggesting that Cxcr4 can compensate for loss of Robo4.
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Figure 6. Combined Loss of Robo4 and
Cxcr4 Function Impaired HSC Localization
to the BM after Transplantation
(A) Preincubationof cellswith increasingamounts of
AMD3100 inhibited migration toward Sdf1 in vitro.
(B) Fewer HSCs localized to the BM 3 hr after trans-
plantation when Robo4 and/or Cxcr4 function was
blocked. CFSE-labeled cells from WT and
Robo4/micewithandwithoutAMD3100preincu-
bationwere injected i.v. into lethally irradiated recip-
ients, followed by tissue analysis for CFSE-positive
cells 3 hr later.
(C) A reciprocal increase of Robo4/ and
AMD3100-treated HSCs was detected in PB 3 hr
after transplantation.
(D) No significant differences in localization to the
spleen were detected.
Data represent three independent experimentswith
three to fourmiceper cohort per experiment (nR9).
Error bars represent SEM. *p < 0.03; **p < 0.003;
***p < 0.0001. See also Figure S6.
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Robo4 Regulates HSC Location to Bone Marrow NichesImportantly, addition of AMD3100 to the Cy/G regimen restored
the mobilization efficiency to WT levels (Figure 4B). This
demonstrates that Cxcr4 and Robo4 act together to retain
HSCs in the BM. Developmental upregulation of Robo4 and
our finding that Robo4 tethers HSCs specifically to BM niches
provide a tantalizing explanation for how HSCs gain Cxcr4 inde-
pendence once seeded in the BM (Sugiyama et al., 2006; Nie
et al., 2008).
Slit2 Does Not Affect HSC Function In Vitro
The role of Slits in Robo4 function has been debated, because
high-affinity, direct binding of Slit2 protein to Robo4 protein
is not detected (Suchting et al., 2005). However, Robo4
expression endows endothelial cells with migratory responses
to Slits (Kaur et al., 2006; Park et al., 2003), and Slit2-mediated
effects in the vasculature and mammary gland are Robo4
dependent (Jones et al., 2008; London et al., 2010; Marlow
et al., 2010). These observations have led to the concept that
a coreceptor enhances the affinity of Slit2 for Robo4. Proposed
coreceptors include Robo1 (Sheldon et al., 2009) and syndecans
(Hu, 2001; Johnson et al., 2004; Steigemann et al., 2004).
Because Robo1 is not expressed by HSCs (Figure S1B), synde-
cans are more likely coreceptor candidates in HSCs. Indeed, we
have previously reported differential regulation of syndecanCell Stem Cell 8, 72–family members between HSCs and
progenitor cells (Forsberg et al., 2005).
To our knowledge, the functional conse-
quences of this differential expression
have not been investigated.
The lack of Slit2 effects onHSCprolifer-
ation and migration in vitro does not
preclude an important role for Slit2 on
HSC function in vivo. Indeed, if Robo4
acts to tether HSCs to BM niches, Slits
would be expected to have little impact
in solution. Instead, lack of Slit2 effects
in vitro supports a role for Slit/Robo
signaling in niche-dependent HSC func-tion. Upregulation of Slit2 during hematopoietic stress (Shibata
et al., 2009) argues for a physiologically important role of Slit2
in HSC function. The relative importance of this role may be
amplified in stress situations, analogous to what has been
observed upon challenges to vascular integrity (Jones et al.,
2008; London et al., 2010; Marlow et al., 2010).
Differential Efficacy of Cxcr4 Manipulation
on Hematopoietic Stem and Progenitor Cells
Cxcr4 is a well-established regulator of HSC localization to the
BM. Surprisingly, however, we found that HSCs express rela-
tively low levels of Cxcr4, both at the transcript and cell surface
protein levels. These results contrast those by Sugiyama and
colleagues, who reported higher Cxcr4 mRNA levels in HSCs
compared to MPP (Sugiyama et al., 2006), but are consistent
with a recent report assaying Cxcr4 expression and hematopoi-
etic cell migration (Sasaki et al., 2009). Importantly, we showed
that differential Cxcr4 expression had functional consequences,
as AMD3100-induced mobilization (Figure 4D) and migration
efficiency toward Sdf1 (Figure 5D) correlated with Cxcr4 expres-
sion levels (Figure 5). Our findings have important implications
for understanding the molecular mechanisms of HSC localiza-
tion next to Sdf1-expressing cells (Sugiyama et al., 2006).
Several cell types, far more numerous than HSCs, express83, January 7, 2011 ª2011 Elsevier Inc. 79
Figure 7. Simplified Model of Robo4- and
Cxcr4-Mediated Control of HSC Migration,
Engraftment, and Mobilization
During developmental transition of HSC location
from fetal liver to BM, or upon transplantation,
HSCs home toward BM niches by the attractant
cues between Cxcr4 and stromal-derived Sdf1.
Adhesive interactions provided by both Cxcr4
and Robo4 promote stable interactions with the
niche with long-term engraftment as a result. B
cells and other cells expressing high levels of
Cxcr4 also home to the BM, but, similar to
Robo4/ HSCs, fail to engage in stable niche
interactions. AMD3100-induced mobilization of
HSCs into the bloodstream is more efficient
when Robo4 is deleted, in spite of increased levels
of Cxcr4.
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Robo4 Regulates HSC Location to Bone Marrow Nicheshigher levels of Cxcr4 (Figure 5) and consequently respond
better to Sdf1 and AMD3100 (Figures 4D and 5D). This includes
myeloid progenitors, B, and T cells. Therefore, molecules other
than Cxcr4must specify location of HSCs to limited niche space.
Indeed, we show that Robo4 collaborates with Cxcr4 to provide
highly HSC-specific localization cues.
Because the molecular mechanisms mobilizing mouse and
human HSCs are remarkably similar, Robo4 cooperation with
Cxcr4 have potentially important clinical implications. A bolus
injection of AMD3100 alone does not yield sufficient numbers
of HSCs for an adult transplant. Therefore, alternative injection
protocols and combinatorial use with other mobilizing agents
have been explored, including continuous AMD3100 infusion,
and AMD3100 combined with G-CSF and integrin a4 inhibitors
(Bonig et al., 2009; Flomenberg et al., 2005; Liles et al., 2003).
A mobilizing agent specifically targeting HSCs, such as an
inhibitor of Robo4-mediated adhesion, may significantly boost
HSC yield.
Robo4 and Cxcr4 Employ Distinct Molecular
Mechanisms to Localize HSCs to the BM
The HSC phenotype upon Robo4 loss is similar to that of condi-
tional deletion or AMD3100-mediated inhibition of Cxcr4. For
example, deletion of Robo4 and AMD3100 treatment resulted
in similar decreases in HSC localization to the BM 3 hr postinjec-
tion (Figure 6B), and at steady state, HSC BM frequencies were
decreased upon either Robo4 (Figure 2A) or Cxcr4 (Sugiyama
et al., 2006) deletion. In addition, both Robo4/ and Cxcr4/
HSCs display lower long-term engraftment but retained lineage
multipotency (Figures 2C and 2D; Nie et al., 2008; Sugiyama
et al., 2006). However, important differences distinguish the
mechanisms of receptor function. Cxcr4 expression endows
HSCs with an active migratory response toward Sdf1, but we
were unable to detect such effects with Slit2. Additionally,
Cxcr4 is expressed by many hematopoietic and nonhemato-
poietic cell types, whereas Robo4 expression is highly selective
for HSCs. Indeed, our functional data demonstrate highly HSC-
specific functions for Robo4.
In a simplified model, chemoattractants, including Sdf1, guide
HSCs to the BM (Figure 7). Once in the vicinity of HSC-
supportive niches, Cxcr4 and Robo4 together promote80 Cell Stem Cell 8, 72–83, January 7, 2011 ª2011 Elsevier Inc.HSC retention in the niche and stable engraftment. The highly
HSC-restricted Robo4 expression probably endows HSCs with
a competitive advantage to limited BM niche space compared
to cells expressing higher levels of Cxcr4, but not Robo4. Inhibi-
tion or loss of Cxcr4 results in fewer HSCs actively migrating
toward niches. Loss of Robo4, on the other hand, probably
results in equal, or because of Cxcr4 upregulation maybe even
greater, numbers of HSCs localizing close to niches. However,
BM localization is transient in the absence of Robo4 because
fewer HSCs engage in stable niche interactions. In both cases,
decreased long-term engraftment is observed. Because of these
dual cooperative adhesive cues, both Robo4- and Cxcr4-medi-
ated interactions with the niche have to be inhibited for efficient
HSC mobilization to the blood; thus, AMD3100-induced HSC
mobilization is more efficient in Robo4-deficient mice.
Receptor Redundancy in the Control of HSC Function
Upregulation of Cxcr4 seems to partially compensate for Robo4
loss and attenuate the phenotype of Robo4/mice. This is sup-
ported by the inefficient HSCmobilization with Cy/G inRobo4/
mice (Figure 3C) and additive effects in BM homing experiments
(Figure 6B). Likewise, engraftment of Cxcr4/ HSCs is likely
possible due to functional redundancy with Robo4 and other
adhesion receptors expressed by HSCs. Although we did not
detect upregulation of Vcam1, Esam1, or CD31 upon Robo4
deletion, these receptors are highly expressed by HSCs
(Figure S3A), and probably contribute to HSC localization (Kikuta
et al., 2000; Ooi et al., 2009; Ross et al., 2008). In the vasculature,
Robo4 intersects with pathways regulated by VE-cadherin and
VEGF receptors. Because VEGF signaling and the sinusoidal
endothelium affects hematopoietic reconstitution (Hooper
et al., 2009), Robo4may also affect hematopoiesis by its expres-
sion in endothelial cells. We recently reported increased defects
in angiogenesis under pathological conditions in Robo4/mice
(Jones et al., 2008) and we also found that Robo4 controls blood
vessel growth during mammary gland development (Marlow
et al., 2010). These reports demonstrated that Robo4 is dispens-
able under homeostatic conditions, but critically important
during tissue perturbation and remodeling. Mechanistically, it
is intriguing that the Sdf1/Cxcr4 axis is upregulated in Robo1/
mammary glands (Marlow et al., 2008). These results point to
Cell Stem Cell
Robo4 Regulates HSC Location to Bone Marrow Nichesconservation of molecular mechanisms across tissues and
between different Robo receptors.
Several molecules have been implicated in HSC homing and
engraftment, but the relationship between these factors and
how they work together to specify HSC location is unclear.
We recently proposed a ‘‘niche code hypothesis,’’ where HSC
location is specified by a combination of factors, much like the
histone code hypothesis dictates transcriptional outcome
(Forsberg and Smith-Berdan, 2009). This model takes into
account the contribution of multiple receptors in regulating
HSC location and function. Such receptor redundancy would
also allowHSCs to respond tomultiple types of cues to stimulate
production of the appropriate cell type. We have begun to
dissect this complex regulation by establishing a functional rela-
tionship between Robo4 and Cxcr4 in controlling HSC location.
A sophisticated understanding of the molecular cues from the
endogenous niche milieu that support HSC self-renewal will be
necessary to overcome our frustrating inability to expand and
generate transplantable HSCs ex vivo.
Therapeutic Potential of Manipulating Robo4 Function
The responsiveness of Robo receptors to soluble ligands
renders them optimal targets for manipulation by natural or
synthetic agonists and antagonists. A relevant precedence is
provided by the clinical utility of Cxcr4 antagonists in hematopoi-
etic cell mobilization. However, Cxcr4 is expressed by many
different cell types, including the brain, leading to significant
effects on non-HSC populations, and genetic Cxcr4 deletion is
embryonic lethal. In contrast, Robo4/ mice are viable with
mild phenotype, and Robo4 expression is restricted to HSCs
and endothelial cells. Thus, pharmacologic manipulation of
Robo4 function will probably be safe and highly specific. Once
potent modulators of Robo4 function have been identified,
Robo4 is a potentially valuable clinical target to improve the
success of HSC transplantation therapy.
EXPERIMENTAL PROCEDURES
Mice
Mice were maintained by the UCSC animal facility according to approved
protocols. Robo4/ mice were described previously (Jones et al., 2008;
London et al., 2010; Marlow et al., 2010). WT mice were generated from het/
het breeding of the Robo4/ mice or purchased C57Bl6 mice from JAX
(Bar Harbor, Maine). Radiation was delivered as a split dose administered
3 hr apart with a Faxitron CP-160 X-ray instrument (Lincolnshire, IL).
Competitive Reconstitution Assays
HSC were isolated from Robo4/ (Ly5.1) or WT (Ly5.1/5.2) donors by two
rounds of FACS and administered i.v. with whole bone marrow helper cells
(3e5 cells) from Ly5.2 congenic hosts. Recipient mice were bled at 3, 6, 9,
12, and 16 weeks posttransplant via the tail vein and peripheral blood was
analyzed for donor chimerism by means of antibodies to the Ly5.1 (Alexa488)
and Ly5.2 (Alexa680) alleles and the lineage markers B220 (APC-Cy7), CD3
(PE), Mac1 (PECy7), Ter119 (PECy5), and Gr1 (Pacific Blue) (eBioscience,
Biolegend, or BD Biosciences). Statistically significant differences for all
comparisons were calculated with two-tailed t tests, unless stated otherwise.
qRT-PCR
Quantitative RT-PCR was performed as described previously (Forsberg et al.,
2005, 2006), except reactions were conducted on a Corbett cycler with the
Quantace SensiMixPlus SYBR. Expression of b-actin was used to normalize
cDNA amounts between samples.Modified Boyden Migration Assays
BM cells (lineage depleted by magnetic selection, when appropriate), were
preincubated at 37C for 1 hr, then placed in the upper chamber of a transwell
insert (5 mm pore size). Bottom and/or top wells contained Sdf1 (100 ng/ml)
and/or Slit2, as indicated. Cells were allowed to migrate for 2 hr at 37C before
harvesting and analysis by flow cytometry.
Cy/G and AMD3100 Mobilization
Mice were mobilized with cytoxan and G-CSF (Cy/G) as previously described
(Morrison et al., 1997). In brief, mice were injected i.p. with 200 mg/kg of
Cytoxan in HBSS (Sigma-Aldrich) on day 1, followed by two or four sequen-
tial daily s.c. injections of 200 mg/kg rhG-CSF (Humanzyme, Chicago, IL).
Tissueswere analyzed on day 2 or 4, as indicated (Figures 3A and 4A). A cohort
from each group was injected i.v. with 5 mg/kg of AMD3100 1 hr prior to sacri-
fice. For AMD3100 alone, mice were treated with two serial AMD3100 (5 mg/
kg) i.v. injections 1 hr apart. Peripheral blood, spleen, and bone marrow
were isolated 1 hr later and processed for cell counts and flow cytometry anal-
ysis to determine the numbers and frequencies of each cell population.
BM Homing Assays
BM cells were labeled with CFSE labeling dye (Invitrogen) for 5 min at rt,
followed by antibody labeling and isolation of cKit+/Linneg/Sca1+/CFSEhi cells
by two rounds of FACS. Sorted cells were split in two equal parts and incu-
bated with or without AMD3100 (12.5 mM) on ice for 30 min. Cells were
washed, pelleted by centrifugation, and resuspended in HBSS at 400,000
cells/ml. Hosts, lethally irradiated 24 hr prior to transplantation, were injected
i.v. with 40,000 cells in 100 ml. Three hours posttransplant, tissues were har-
vested from individual mice and analyzed for CFSE-labeled cells by flow
cytometry.
SUPPLEMENTAL INFORMATION
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